Immunohistochemical evaluation of HER2 expression in canine thyroid carcinoma

The human epidermal growth factor receptor 2 (HER2) is expressed in various human cancers including thyroid cancers (TC) and is used as a diagnostic marker and therapeutic target. Canine TC (cTC), the most common endocrine malignancy in dogs, shows a high metastasis rate, and HER2-targeted therapy c...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshimoto, Sho, Kato, Daiki, Kamoto, Satoshi, Yamamoto, Kie, Tsuboi, Masaya, Shinada, Masahiro, Ikeda, Namiko, Tanaka, Yuiko, Yoshitake, Ryohei, Eto, Shotaro, Saeki, Kohei, Chambers, James, Kinoshita, Ryohei, Uchida, Kazuyuki, Nishimura, Ryohei, Nakagawa, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6639692/
https://www.ncbi.nlm.nih.gov/pubmed/31360780
http://dx.doi.org/10.1016/j.heliyon.2019.e02004
Descripción
Sumario:The human epidermal growth factor receptor 2 (HER2) is expressed in various human cancers including thyroid cancers (TC) and is used as a diagnostic marker and therapeutic target. Canine TC (cTC), the most common endocrine malignancy in dogs, shows a high metastasis rate, and HER2-targeted therapy could be a candidate for treatment. Here, we immunohistochemically evaluated HER2 expression in 21 paraffin-embedded cTC tissues and scored the degree of expression based on intensity and positivity (score: 0–3+). Four samples (19%) scored 3+; 6 (29%), 2+; 7 (33%), 1+; and 4 (19%), 0. Therefore, 48% of the cTC tissues were HER2 positive (scored ≥2+). These data may lead to further evaluation of the role of HER2 in cTC as a mechanism of malignancy and a therapeutic target.

Ejemplares similares